Result of General Meeting
CRISM Therapeutics Corporation announced that all resolutions were unanimously passed at its General Meeting, with over 99.97% of votes in favour for both resolutions. This signifies shareholder approval for the company's funding round, which, combined with recent grant finance, positions CRISM Therapeutics strongly to execute its strategy. Admission of 22,500,000 Conditional Placing Shares and 2,450,000 Retail Offer Shares is expected on 16 June 2026, bringing the total issued share capital to 79,185,266 Ordinary Shares. Additionally, 25,000,000 Warrants exercisable at 15 pence have been granted.
Select text to share a quote on X · sign in to keep highlights & notes in your CRTX notes
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.
CRISM Therapeutics Corporation
('CRISM', 'CRISM Therapeutics' or the 'Company')
Result of General Meeting
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, is pleased to announce that all Resolutions were duly passed unanimously on a show of hands at the Company's General Meeting, which was held today at 10:00 a.m.
The votes cast were as follows:
| Resolution | Votes for | % for | Votes against | % against | Abstentions |
|---|---|---|---|---|---|
| 1 | 7,895,490 | 99.97 | 2,182 | 0.03 | 996 |
| 2 | 7,895,440 | 99.97 | 2,232 | 0.03 | 996 |
Andrew Webb, Executive Chairman of CRISM Therapeutics, said: "We would like to thank our existing shareholders as well as welcome new investors who have supported and participated in this funding round, which has now successfully completed. When combined with the grant finance that we recently announced, the Company is now in a strong financial position to execute on our stated strategy and we look forward to reporting on further milestones in the weeks ahead."
Admission and Total Voting Rights
Application has been made to the London Stock Exchange for admission of the 22,500,000 Conditional Placing Shares and 2,450,000 Retail Offer Shares ('Admission'). It is expected that Admission will become effective and that trading will commence in the Conditional Placing Shares and Retail Offer Shares at 8.00 a.m. on 16 June 2026. The Conditional Placing Shares and the Retail Offer Shares will rank pari passu with the Company's existing Ordinary Shares.
In addition, 25,000,000 Warrants, exercisable at a price of 15 pence per ordinary share and expiring on 16 December 2027, have been granted to subscribers for the Placing Shares.
Following Admission, the total issued share capital of the Company will consist of 79,185,266 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company will be 79,185,266 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
Capitalised terms not defined have the same meaning as given to them in the Company's Circular dated 27 May 2026.
The Company's LEI is 213800XFW6MKVCHHPW88.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.